Protego Biopharma closed an oversubscribed $130 million Series B to advance PROT‑001, its oral candidate for AL (light‑chain) amyloidosis, toward a pivotal study. The round was led by Novartis Venture Fund and Forbion, with participation from specialist and life‑science investors. Protego’s molecule aims to stabilize misfolded immunoglobulin light chains — an approach intended to improve outcomes where antibody programs from larger players recently failed. The financing funds regulatory and clinical work, positioning Protego to enter registrational testing next year.